[HTML][HTML] The drug repurposing for COVID-19 clinical trials provide very effective therapeutic combinations: lessons learned from major clinical studies
SARS-CoV-2 has spread across the globe in no time. In the beginning, people suffered due
to the absence of efficacious drugs required to treat severely ill patients. Nevertheless, still …
to the absence of efficacious drugs required to treat severely ill patients. Nevertheless, still …
[HTML][HTML] Development and application of therapeutic antibodies against COVID-19
L Ning, HB Abagna, Q Jiang, S Liu… - International journal of …, 2021 - ncbi.nlm.nih.gov
The pandemic of Coronavirus disease 2019 (COVID-19) caused by the severe acute
respiratory syndrome 2 coronavirus (SARS-CoV-2) continues to be a global health crisis …
respiratory syndrome 2 coronavirus (SARS-CoV-2) continues to be a global health crisis …
[HTML][HTML] Antibody escape of SARS-CoV-2 Omicron BA. 4 and BA. 5 from vaccine and BA. 1 serum
A Tuekprakhon, R Nutalai, A Dijokaite-Guraliuc… - Cell, 2022 - cell.com
The Omicron lineage of SARS-CoV-2, which was first described in November 2021, spread
rapidly to become globally dominant and has split into a number of sublineages. BA. 1 …
rapidly to become globally dominant and has split into a number of sublineages. BA. 1 …
[HTML][HTML] SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses
On 24 th November 2021, the sequence of a new SARS-CoV-2 viral isolate Omicron-B. 1.1.
529 was announced, containing far more mutations in Spike (S) than previously reported …
529 was announced, containing far more mutations in Spike (S) than previously reported …
[HTML][HTML] Potent cross-reactive antibodies following Omicron breakthrough in vaccinees
Highly transmissible Omicron variants of SARS-CoV-2 currently dominate globally. Here, we
compare neutralization of Omicron BA. 1, BA. 1.1, and BA. 2. BA. 2 RBD has slightly higher …
compare neutralization of Omicron BA. 1, BA. 1.1, and BA. 2. BA. 2 RBD has slightly higher …
[HTML][HTML] A delicate balance between antibody evasion and ACE2 affinity for Omicron BA. 2.75
Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have caused
successive global waves of infection. These variants, with multiple mutations in the spike …
successive global waves of infection. These variants, with multiple mutations in the spike …
[HTML][HTML] Rapid escape of new SARS-CoV-2 Omicron variants from BA. 2-directed antibody responses
Summary In November 2021, Omicron BA. 1, containing a raft of new spike mutations,
emerged and quickly spread globally. Intense selection pressure to escape the antibody …
emerged and quickly spread globally. Intense selection pressure to escape the antibody …
The smallest functional antibody fragment: ultralong CDR H3 antibody knob regions potently neutralize SARS-CoV-2
Cows produce antibodies with a disulfide-bonded antigen-binding domain embedded within
ultralong heavy chain third complementarity determining regions. This “knob” domain is …
ultralong heavy chain third complementarity determining regions. This “knob” domain is …
Conformational dynamics and allosteric modulation of the SARS-CoV-2 spike
MA Díaz-Salinas, Q Li, M Ejemel, L Yurkovetskiy… - Elife, 2022 - elifesciences.org
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects cells through
binding to angiotensin-converting enzyme 2 (ACE2). This interaction is mediated by the …
binding to angiotensin-converting enzyme 2 (ACE2). This interaction is mediated by the …
[HTML][HTML] Passive immunotherapy against SARS-CoV-2: from plasma-based therapy to single potent antibodies in the race to stay ahead of the variants
The COVID-19 pandemic is now approaching 2 years old, with more than 440 million people
infected and nearly six million dead worldwide, making it the most significant pandemic …
infected and nearly six million dead worldwide, making it the most significant pandemic …